Synthèse de la <scp>L</scp>‐arginyl‐<scp>L</scp>‐prolyl‐<scp>L</scp>‐prolyl‐glycyl‐<scp>L</scp>‐phénylalanyl‐<scp>L</scp>‐Séryl‐<scp>L</scp>‐phénylalanyl‐<scp>L</scp>‐arginine. Distinction entre cet octapeptide et la bradykinine

Abstract

Abstract By condensing N–CBO‐nitro‐ L ‐arginyl‐ L ‐prolyl‐ L ‐prolyl‐glycyl azide or the corresponding p‐nitrophenyl ester with L ‐phenylalanyl‐ L ‐seryl‐ L ‐phenylalanyl‐nitro‐ L ‐arginine‐p‐nitrobenzyl ester, N‐CBO‐nitro‐ L ‐arginyl‐ L ‐prolyl‐ L ‐prolyl‐glycyl‐ L ‐phenylalanyl‐ L ‐seryl‐ L ‐phenylalanyl‐nitro‐ L ‐arginine p‐nitrobenzyl ester has been obtained. The same protected octapeptide has also been prepared by condensing N‐CBO‐nitro‐ L ‐arginyl‐ L ‐proline with L ‐prolyl‐glycyl‐ L ‐phenylalanyl‐ L ‐seryl‐ L ‐phenylalanyl‐nitro‐ L ‐arginine p‐nitrobenzyl ester. Catalytic hydrogenation of the protected octapeptide affords L ‐arginyl‐ L ‐prolyl‐ L ‐prolyl‐glycyl‐ L ‐phenylalanyl‐ L ‐seryl‐ L ‐phenylalanyl‐ L ‐arginine, the identity of which has been checked by several methods. This octapeptide does not possess any of the biological properties of bradykinin; it also differs from the latter by its comportment toward chymotrypsin.